Doxorubicin hydrochloride
Cat. No.：YN250620
CAS No. ：25316-40-9
| 产品名称: | Doxorubicin hydrochloride |
| CAS No.: | 25316-40-9 |
| Chemical Name: | (8S,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione, monohydrochloride |
| Synonyms: | 盐酸阿霉素; Hydroxydaunorubicin hydrochloride |
| 分子量: | 579.98 |
| 分子式: | C₂₇H₃₀ClNO₁₁ |
| SMILES: | COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.[H]Cl |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride) 是一种有细胞毒性的蒽环类抗生素，常用作肿瘤化疗剂。Doxorubicin hydrochloride 抑制拓扑异构酶 II (topoisomerase-II)，IC50为 2.67 μM，从而抑制 DNA 复制。Doxorubicin hydrochloride 下调AMPK的基础磷酸化以及下游 acetyl-CoA 羧化酶。Doxorubicin hydrochloride 诱导 |
| IC50和靶点: | [{name:"Topoisomerase I:0.8 μM (IC50)"},{name: "Topoisomerase II:2.67 μM (IC50)'}, 'Daunorubicins/Doxorubicins', 'HIV-1'] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Patel, S., Sprung, A.U., Keller, B.A., et al.Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: Implications for the mechanisms of doxorubicin action and cytotoxicityMol. Pharmacol.52(4),658-666(1997)
Lorenzo, E., Ruiz-Ruiz, C., Quesada, A.J., et al.Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanismJ. Biol. Chem.277(17),10883-10892(2002)
